Pfizer Inc. (NYSE:PFE) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP raised its position in Pfizer Inc. (NYSE:PFE) by 6.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 765,736 shares of the biopharmaceutical company’s stock after buying an additional 43,193 shares during the period. Trexquant Investment LP’s holdings in Pfizer were worth $20,315,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Citigroup reduced their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of PFE opened at $25.36 on Tuesday. The firm has a 50-day simple moving average of $26.05 and a two-hundred day simple moving average of $26.88. The stock has a market cap of $143.80 billion, a PE ratio of 17.98, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.